Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Active Filter(s):
Details:
Under the terms of the agreement, Mylan Ireland Limited will acquire the commercialisation rights and related intellectual property relating to Aspen’s Thrombosis Business in Europe which includes Arixtra, Fraxiparine, Mono-Embolex and Orgaran.
Lead Product(s): Fondaparinux Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Arixtra
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Viatris
Deal Size: $757.2 million Upfront Cash: $310.4 million
Deal Type: Acquisition September 08, 2020
India Med Expo
Not Confirmed
Contact Supplier
